Patheon to Feature Softgel Technology at CPHi Worldwide Conference in Spain
Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its world class softgel technology, including Unigel™, at the CPHi Worldwide conference in Madrid, Spain on October 9-11, 2012. An exclusive feature to Patheon’s Unigel™ helps to overcome challenges faced with difficult-to-develop formulations with multiple APIs. Unigel™ is the first dosage format that allows the combination of softgels within softgel, or tablets, beads or pellets within softgel. This technology opens the door to a wide variety of innovative formulation approaches, which can be used for life cycle management strategies or new chemical entities. Some of the technology’s distinct benefits include:
- Multiple active ingredients
- Incompatible materials with different release profiles
- Liquids, granules, solids and hard capsules
- Fast and sustained release
- Gastric and intestinal release
Launched earlier this year, pharmaceutical companies are already taking advantage of the unique offering and projects are ongoing. The softgel technology offers pharmaceutical companies shorter lead times, more manufacturing flexibility, freedom from intellectual property restrictions and a broad range of dosage formats that are leading technologies, such as Unigel™.
A presentation “Unlocking the Power of New Softgel Technology for Multiple API Formulations: Unigel” will be given at the ICSE Speaker’s Corner (10C78 in Hall 10) on Tuesday, October 9, 2012, at 2:30 p.m. Central European Time. For more information on upcoming events, visit Patheon's Knowledge Library.
Patheon representatives, along with the company’s partners, Softigel, will be available to meet at the CPHi Worldwide conference in Madrid, Spain on October 9-11, 2012, and at the AAPS Annual Meeting and Exposition in Chicago, Illinois on October 14-18, 2012.
To schedule an interview with Patheon during either conference, please contact Jennifer Almond at media@Patheon.com.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
Softigel, a part of the Procaps Group, is a pioneer in softgels and one of the world’s largest manufacturers. Five of the top 12 global pharmaceutical companies, and many others, all trust Softigel for their softgel supply.
View original release here: http://www.prweb.com/releases/2012/10/prweb9976966.htm